Literature DB >> 19120021

Functional significance of a putative sp1 transcription factor binding site in the survivin gene promoter.

M V Mityaev1, E P Kopantzev, A A Buzdin, T V Vinogradova, E D Sverdlov.   

Abstract

We sequenced 1500-bp genomic DNA regions upstream from the survivin gene (BIRC5). DNA was isolated from human placenta and tumors of patients with diagnosed squamous cancer of the lung that showed high-level BIRC5 gene expression. We have revealed four new promoter allelic variants differing in single nucleotide substitutions, one variant with two nucleotide substitutions, and a variant with a TAAA tetranucleotide insertion. All promoter variants displayed low activity in cells with functionally active p53 protein and high activity in cell lines characterized by low level or absence of p53 protein function. The activity of the promoters with single nucleotide substitutions was comparable to that of the wild-type promoter, whereas two nucleotide substitutions markedly reduced the activity. We also demonstrated the functional significance of a putative Sp1 transcription factor-binding site at (-63...-54) upstream from the transcription initiation site. Mutation within this sequence led to a sharp decrease of promoter activity. The functional architecture of the survivin promoter is discussed based on results known from the literature and those obtained here.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19120021     DOI: 10.1134/s0006297908110035

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  22 in total

1.  Bicistronic vector for combined expression of the HSVtk killer gene and cytokine GM-CSF gene in cancer cells.

Authors:  I V Alekseenko; E P Kopantzev; T V Vinogradova; E D Sverdlov
Journal:  Dokl Biochem Biophys       Date:  2011 Jul-Aug       Impact factor: 0.788

Review 2.  Epigenetic mechanism of survivin dysregulation in human cancer.

Authors:  Hui Lyu; Jingcao Huang; Zhimin He; Bolin Liu
Journal:  Sci China Life Sci       Date:  2018-01-04       Impact factor: 6.038

3.  Significant biological role of sp1 transactivation in multiple myeloma.

Authors:  Mariateresa Fulciniti; Samir Amin; Puru Nanjappa; Scott Rodig; Rao Prabhala; Cheng Li; Stephane Minvielle; Yu-Tzu Tai; Pierfrancesco Tassone; Herve Avet-Loiseau; Teru Hideshima; Kenneth C Anderson; Nikhil C Munshi
Journal:  Clin Cancer Res       Date:  2011-08-19       Impact factor: 12.531

Review 4.  Association between survivin -31G>C polymorphism and cancer risk: meta-analysis of 29 studies.

Authors:  Qin Qin; Chi Zhang; Hongcheng Zhu; Xi Yang; Liping Xu; Jia Liu; Jing Lu; Liangliang Zhan; Hongyan Cheng; Xinchen Sun
Journal:  J Cancer Res Clin Oncol       Date:  2014-02       Impact factor: 4.553

5.  Survivin -31C/G polymorphism and gastric cancer risk in a Brazilian population.

Authors:  Bárbara do Nascimento Borges; Rommel Rodriguez Burbano; Maria Lúcia Harada
Journal:  Clin Exp Med       Date:  2010-12-16       Impact factor: 3.984

6.  WMJ-8-B, a novel hydroxamate derivative, induces MDA-MB-231 breast cancer cell death via the SHP-1-STAT3-survivin cascade.

Authors:  Yu-Fan Chuang; Shiu-Wen Huang; Ya-Fen Hsu; Meng-Chieh Yu; George Ou; Wei-Jan Huang; Ming-Jen Hsu
Journal:  Br J Pharmacol       Date:  2017-08-01       Impact factor: 8.739

7.  Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies.

Authors:  Lei Xu; Xin Zhou; Lin Xu; Rong Yin
Journal:  Tumour Biol       Date:  2013-10-05

8.  Anti-leukemic response of a NSAID, tolfenamic acid.

Authors:  Robert M Sutphin; Sarah F Connelly; Chris M Lee; Umesh T Sankpal; Don Eslin; Moeez Khan; Hima Pius; Riyaz Basha
Journal:  Target Oncol       Date:  2013-04-23       Impact factor: 4.493

9.  Novel interactions between the HTLV antisense proteins HBZ and APH-2 and the NFAR protein family: Implications for the HTLV lifecycles.

Authors:  Jane Murphy; William W Hall; Lee Ratner; Noreen Sheehy
Journal:  Virology       Date:  2016-04-22       Impact factor: 3.616

10.  OCT4 increases BIRC5 and CCND1 expression and promotes cancer progression in hepatocellular carcinoma.

Authors:  Lu Cao; Chunguang Li; Shuwen Shen; Yan Yan; Weidan Ji; Jinghan Wang; Haihua Qian; Xiaoqing Jiang; Zhigang Li; Mengchao Wu; Ying Zhang; Changqing Su
Journal:  BMC Cancer       Date:  2013-02-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.